MDC are focusing on cancer related pain. Auscann are focussing on chronic pain and neuropathic pain... two different areas. In terms of market cap, its the cultivation licences that are giving auscann a higher value as theyll be growing and making a medicine not just making the medicine. Both great stocks though, i hold both, but they arent directly competing with eachother though
- Forums
- ASX - By Stock
- AC8
- Canabis has no benefit for chronic pain
Canabis has no benefit for chronic pain, page-21
Featured News
Add AC8 (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AC8 (ASX) Chart |
Day chart unavailable